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Defects in insulin secretion play a central role in the
pathogenesis of type 2 diabetes, yet themechanisms
driving beta-cell dysfunction remain poorly under-
stood, and therapies to preserve glucose-dependent
insulin release are inadequate. We report a lumines-
cent insulin secretion assay that enables large-scale
investigations of beta-cell function, created by insert-
ing Gaussia luciferase into the C-peptide portion of
proinsulin. Beta-cell lines expressing this construct
cosecrete luciferase and insulin in close correlation,
under both standard conditions or when stressed
by cytokines, fatty acids, or ER toxins. We adapted
the reporter for high-throughput assays and per-
formed a 1,600-compound pilot screen, which identi-
fied several classes of drugs inhibiting secretion, as
well as glucose-potentiated secretagogues that
were confirmed to have activity in primary human is-
lets. Requiring 40-fold less time and expense than the
traditional ELISA, this assaymay accelerate the iden-
tification of pathways governing insulin secretion and
compounds that safely augment beta-cell function in
diabetes.
INTRODUCTION
Type 2 diabetes (T2D) represents a global health epidemic that is
predicted to double in prevalence over the next 20 years,
causing blindness, amputation, neuropathy, and life-threatening
macrovascular complications (Boyle et al., 2010). The disease is
characterized by impaired insulin action in target organs and a
failure of insulin secretion to compensate for this defect. Pro-
gression of disease correlates closely with decreases in insulin126 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Insecretion (Fonseca, 2009), and human genetic studies of both
Mendelian and common forms of diabetes have highlighted a
central role of beta-cell dysfunction in the inherited basis of
T2D (Ingelsson et al., 2010). Identifying the mechanisms by
which beta cells fail in diabetes, and targeting such pathways
therapeutically, could prevent the development of the condition
and significantly improve its treatment.
Historically, assays of beta-cell function have relied on the
ELISA, the gold standard for measuring insulin. This method,
while of critical importance to the field, is characterized by multi-
ple liquid-handling steps, limited dynamic range, and high
cost (> $2 per sample), making it challenging for use in high-
throughput applications. Recently, 384-well insulin assays based
on fluorescence resonance energy transfer (FRET) have become
commercially available (Degorce, 2006; Bielefeld-Sevigny,
2009). While these assays enable larger format experiments,
they remain relatively expensive ($0.60–$1.70 per sample),
require supernatant transfer steps, and involve plate readers
with advanced hardware compatible with these methods (i.e.,
time-resolved FRET; AlphaLISA laser-based detection). As a
consequence, only two small-scale chemical screens of insulin
secretion have been published to date, and the size of each
(1,280 and 4,691 compounds) limited their ability to detect novel
insulinotropic compounds (Wu et al., 2008; Lee et al., 2011).
Several groups have attempted to circumvent the ELISA using
surrogate markers of insulin secretion, by fusing either GFP or
luciferase to the end of the insulin propeptide (Pouli et al., 1998;
Liu et al., 2007; Suzuki et al., 2011). While some have been useful
for tracking exocytotic events, none have demonstrated correla-
tion with the insulin ELISA. Moreover, the constructs appear to
have detrimental effects on cell function, possibly due to protein
misfolding. Over 95% of a proinsulin-firefly luciferase fusion
protein is retained in the ER, and cells expressing a proinsulin-
Gaussia luciferase construct show less than 3-fold induction of
secretion upon maximal glucose stimulation.
A rapid and inexpensive way of tracking insulin secretion
would enable the systematic and comprehensive evaluation ofc.
genetic and environmental factors contributing to insulin defi-
ciency in diabetes and the search for compounds reversing
these defects. Here, we report the design and validation of a
luminescent insulin secretion assay created by insertingGaussia
luciferase within the C-peptide portion of the insulin prohor-
mone, flanked by additional prohormone convertase cleavage
sites. Upon stimulation with known insulin secretagogues, beta
cells expressing this reporter secrete luciferase in close correla-
tion with insulin, under standard conditions as well as upon
induction of cellular stress. At a cost of $0.05 per sample, the
assay requires > 40-fold less time and expense than the tradi-
tional ELISA. Moreover, it performs well in high-throughput
applications, and can be used without a supernatant transfer
step. Using the reporter, we performed a proof-of-principle,
1,600-compound screen, under both low- and high-glucose
conditions, identifying several small molecule modulators of
beta-cell secretion. Top-scoring compounds from the high-
glucose screen were subsequently confirmed to augment
glucose-stimulated insulin secretion (GSIS) from cadaveric is-
lets, validating the relevance of the assay to human biology.
Moreover, one of the drugs found to decrease secretion in our
screen, fenofibrate, was subsequently confirmed to inhibit insu-
lin secretion from human islets, demonstrating the potential of
the assay for identifying negative effects of commonly used
medications on beta-cell function.
RESULTS
Creating a Luminescent Insulin Secretion Reporter
We reasoned that luciferase could be used to track insulin secre-
tion if properly targeted to the secretory vesicles within the beta
cell via the endogenous proinsulin processing pathway, in a
manner that preserved the activity of the enzyme. To accomplish
this, we constructed a fusion protein in which the sequence of
Gaussia luciferase was placed within the C-peptide portion of
mouse proinsulin, a fragment that is normally cleaved within
the vesicles by pH-sensitive prohormone convertase enzymes
and cosecreted with mature insulin during exocytosis (Oyer
et al., 1971). Gaussia luciferase was chosen because it is the
smallest and brightest luciferase identified to date (Tannous
et al., 2005). To ensure full activity of the luciferase, a version
was used that was codon-optimized for expression in mamma-
lian cells, and we flanked the enzyme with additional cleavage
sites for prohormone convertase 2 (PC2), such that no extra
amino acids would be present on the ends of the enzyme after
processing within the vesicles (Figure 1A).
In the absence of a suitable glucose-responsive human beta-
cell line, we created both mouse (MIN6; Miyazaki et al., 1990)
and rat (INS-1E; Merglen et al., 2004) beta-cell lines stably ex-
pressing the reporter construct. Each line was indistinguishable
from its wild-type counterpart in terms of morphology, replica-
tion rate, and viability. The luminescent reporter of insulin secre-
tion was validated in both cell lines, with highly similar results
between species.
Upon challenging INS-1E cells expressing the reporter with
varying concentrations of glucose for 1 hr, secretion of insulin
and luciferase were highly correlated (r2 = 0.99; Figures 1B and
1C). Similar results were obtained from MIN6 cells (Figure S1
available online). To confirm that the proinsulin-luciferase fusionCellprotein tracked with insulin and was not retained in the ER,
immunohistochemistry was performed on single cells. Confocal
imaging revealed nearly complete colocalization of insulin and
luciferase within the secretory granules, suggesting that the
fusion protein folds properly and enters the natural proinsulin-
processing pathway (Figures 1D, 1E, and S2). Next, to determine
if the reporter could be used to track insulin secretion from hu-
man beta cells, dissociated human islets were transduced with
a lentiviral expression vector containing the reporter. Upon stim-
ulation of these cells with varying glucose levels, luciferase and
insulin were secreted in close correlation (Figure 1F). The effect
of the fusion construct on beta-cell function and endogenous in-
sulin secretion was then evaluated by comparing the C-peptide
response of cells with and without the transgene. No significant
difference was found upon stimulation with glucose, suggesting
that, unlike other reported fusion proteins, our reporter does not
impair normal insulin processing (Figure 1G).
We further tested the time course of glucose-stimulated
secretion in the INS-1E cell line, observing a predominantly mo-
nophasic pattern, with the magnitude of secretion increased by
the known glucose-dependent insulin secretagogue 3-isobutyl-
1-methylxanthine (IBMX; Figure 1H). To confirm that cells ex-
pressing the reporter secrete luciferase via the regulated insulin
secretion pathway, we examined the effect of diazoxide, a com-
pound known to hyperpolarize the beta cell and inhibit insulin
secretion. As expected, the compound also inhibited luciferase
secretion from cells expressing the fusion protein (Figure 1I).
Verifying the Reporter with Known Secretagogues
To determine if the fusion construct could reliably report insulin
secretion across a broad range of stimuli, we applied a panel
of known secretagogues to cells expressing the reporter,
including small molecules, metabolites, and hormones known
to affect insulin secretion. Luciferase secretion increased as pre-
dicted for each treatment (Figure 2A). The depolarizing agents,
potassium chloride and glipizide, triggered insulin secretion
even in the absence of glucose, though glucose amplified the
amount of secretion in a concentration-dependent manner. In
contrast, a glucokinase activator increased secretion primarily
in the presence of permissive glucose levels, left-shifting the
glucose response curve of the cells, but not affecting their
maximal response. The amino acid arginine exhibited a modest
glucose-dependent effect on luciferase secretion, as did the in-
cretin hormone glucagon-like peptide-1 (GLP-1). Increasing
levels of the secondary messenger cyclic adenosine monophos-
phate (cAMP) using either IBMX or forskolin led to a profound in-
crease in luciferase secretion at higher glucose levels. Likewise,
phorbol 12-myristate 13-acetate (PMA), a compound known to
augment insulin secretion through stimulatory effects on protein
kinase C, had a large effect on secretion. Luciferase activity re-
mained highly correlated with secreted insulin as measured by
ELISA (Figure 2B).
The reporter was further evaluated by performing dose-
response studies using two well-studied glucose-dependent in-
sulin secretagogues with distinct mechanisms of action: IBMX
and a glucokinase activator. As expected, IBMX increased
secretion of luciferase from the cells only in the presence of
high glucose (Figure 2C). In contrast, the glucokinase activator
did not stimulate additional secretion in high glucose, but didMetabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inc. 127
Figure 1. Proinsulin-Luciferase Fusion Protein Faithfully Reports Glucose-Stimulated Insulin Secretion
(A) Diagram of proinsulin-luciferase fusion construct, showing Gaussia luciferase without its signal peptide, inserted within the C-peptide portion of mouse
proinsulin, with added cleavage sites for prohormone convertase 2 (PC2).
(B) Glucose-stimulated secretion of luciferase (red) and insulin (blue) from INS-1E cells expressing the fusion construct; data represent mean ± SD (n = 8).
(C) Correlation between insulin concentration and luciferase activity of samples shown in (B). See also Figure S1 for correlation in MIN6 cells.
(D) Immunohistochemistry of INS-1E cells expressing the proinsulin-luciferase reporter, stained for luciferase (green, left), insulin (red, middle), or both (merged,
right); scale bar, 10 mm.
(E) Quantification of insulin and luciferase colocalization on a pixel-by-pixel basis from INS-1E images in Figure S2.
(F) Correlation between insulin concentration and luciferase activity of dissociated human pancreatic islets expressing the reporter, treated with 2.8 mM, 5.6 mM,
11.1 mM, and 16.7 mM glucose.
(G) Secretion of endogenous C-peptide from wild-type and reporter-containing INS-1E cells; data represent mean ± SD (n = 8).
(H) Time course of glucose-stimulated insulin secretion in INS-1E cells in the presence and absence of known insulin secretagogue IBMX (100 mM). Time zero
value corresponds to preincubation in 2.8mMglucose for 5min, whereas all subsequent time points correspond to incubation in 16.7mMglucose; data represent
mean ± SD (n = 12).
(I) Effect of diazoxide on luciferase secretion from INS-1E cells, in both basal and glucose-stimulated states; data represent mean ± SD (n = 8).augment secretion in low glucose when tested at higher concen-
trations (Figure 2D), consistent with the relative glucose-depen-
dent nature of this class of secretagogue (Rees andGloyn, 2013).
Tracking Beta-Cell Function under Stress
The toxic environment of the beta cell has been implicated in the
pathogenesis of both forms of diabetes, and therapies that coun-
teract this detrimental milieu may reverse the course of disease
(Wajchenberg, 2007). To evaluate the luminescent reporter in
this setting, beta-cell dysfunction was induced using three es-128 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Intablished negative mediators: inflammatory cytokines, saturated
fatty acids, and ER stress-inducing agents.
Cells expressing the luminescent reporter were treated for
24 hr with a cocktail of cytokines known to be elevated in T2D
(Donath et al., 2010), including interleukin-1-beta (IL1b), tumor
necrosis factor-alpha (TNFa), and interferon-gamma (IFN-g),
prior to stimulating luciferase secretion with varying glucose
concentrations. As expected, luciferase secretion at physiologic
and high-glucose levels decreased in proportion to the concen-
tration of cytokines applied to the cells (Figure 2E).c.
Figure 2. Reporter Responds Appropriately to Known Insulin Secretagogues and Beta-Cell Stressors
(A) Luciferase secretion induced by known insulin secretagogues. MIN6 cells were treated for 1 hr at the indicated glucose concentrations with either DMSO,
2.5 mM glucokinase (GK) activator, 25 mM glipizide, 40 mM potassium chloride (KCl), 20 mM arginine, 1 nM glucagon-like peptide-1 (GLP-1), 20 mM forskolin,
50 mM IBMX, or 20 mM phorbol 12-myristate 13-acetate (PMA); data represent the mean ± SD (n = 4).
(B) Correlation between insulin and luciferase secretion as shown in (A) fromMIN6 cells treated with DMSO, glipizide, KCl, GK activator, arginine, and GLP-1; data
represent mean ± SD (n = 4).
(C) Dose-response relationship for IBMX in low (2.8 mM) and high (16.7 mM) glucose in INS-1E cells; data represent mean ± SD (n = 4).
(D) Dose-response relationship for a GK activator in low (2.8 mM) and high (16.7 mM) glucose in INS-1E cells; data represent mean ± SD (n = 4).
(E–G) Effect on glucose-stimulated insulin secretion (GSIS) of pretreating INS-1E cells with increasing concentrations of known beta-cell stressors.
Data represent mean ± SD (n = 4). (E) 24 hr pretreatment with cytokine cocktail containing interleukin-1-beta (13 = 10 ng/ml), tumor necrosis factor-alpha (13 =
25 ng/ml), interferon-alpha (13 = 50 ng/ml). (F) 24 hr pretreatment with the saturated fatty acid palmitate at various concentrations. (G) 8 hr pretreatment with
thapsigargin, a known inducer of ER stress, at various concentrations.Next, lipotoxicity was induced in the reporter cell line using the
saturated fatty acid palmitate. Cells were pretreated with a low
dose of palmitate for 24 hr to induce lipotoxicity, as chronic
exposure to free fatty acids has been implicated in impaired in-
sulin secretion (Hoppa et al., 2009). Upon stimulation of the cells,
luciferase secretion was slightly increased at low-glucose levels
and profoundly decreased at higher glucose levels (Figure 2F),
consistent with published reports (Elks, 1993).
Finally, the effect of ER stress on luciferase release was tested
using thapsigargin, a known inhibitor of the sarcoplasmic and ER
calcium channel (SERCA; Lytton et al., 1991). After 8 hr of treat-
ment with this compound, glucose-stimulated luciferase secre-Celltion dropped substantially and in a dose-dependent manner
(Figure 2G).
Adapting the Reporter to High-Throughput Screening
Applications
To enable large-scale chemical and genetic experiments on in-
sulin secretion, the luminescence assay was adapted to 384-
well and 1,536-well formats, using a streamlined approach that
limited liquid handling steps by performing the assay on cells
in suspension. Though secretion from cells in suspension is
less than from adherent cells (Figure S3), rodent beta-cell lines
respond reproducibly to stimuli in this format, enabling glucoseMetabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inc. 129
Figure 3. High-Throughput Chemical Screen Performed in Low Glucose Identifies Compounds that Trigger or Inhibit Insulin Secretion
(A) Results of a high-throughput screen of 1,600 known bioactive compounds for effects on luciferase secretion from INS-1E cells expressing the proinsulin-
luciferase construct, in the presence of low glucose (2.8 mM), with linear correlation between replicates (r2 = 0.80); test compounds (blue), DMSO negative
controls (green), IBMX (100 mM) positive control (red), KCl (30 mM) positive control (orange). Boxed area shown in greater detail below.
(B) Analysis by class of the 100 top-scoring (red) and 100 bottom-scoring (blue) compounds in the screen, based on reported mechanisms. Number of com-
pounds in each class is shown. a-AR, alpha-adrenergic receptor; b-AR, beta-adrenergic receptor; Na, sodium; K, potassium; Ca, calcium; SSRI, selective
serotonin reuptake inhibitor; cAMP, cyclic adenosine monophosphate; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; SERM, selective estrogen re-
ceptor modulator. See also Figure S3 for comparison of secretion from suspension versus adherent INS-1E cells.starvation and wash steps to be performed prior to plating cells,
which greatly reduces well-to-well variability. In addition, as
more cells can be plated per well in suspension, the signal inten-
sity per well is increased significantly.
In this format, secreted luciferase can be measured either by
directly adding the substrate coelenterazine to each well in a
homogenous manner, or by transferring the supernatant into
an empty plate before adding coelenterazine. The transfer
step decreases the background signal, yet the assay still per-
forms well without this step, with ample separation of positive
and negative controls. For comparison, the Z0 factor of the
assay (Zhang et al., 1999) is > 0.6 when performed in 384-well
format with a transfer step, > 0.5 in 384-well format without a
transfer step, and > 0.35 in 1,536-well format without a transfer
step, using IBMX as the positive control and a glucose concen-
tration of 11.1 mM.
Performing a Pilot Chemical Screen in Low Glucose
After establishing the suitability of the luminescent reporter for
high-throughput applications, we performed a pilot small mole-
cule screen in INS-1E cells using a collection of 1,600 known130 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inbioactive compounds and natural products, using IBMX and po-
tassium chloride as positive controls. Each compound was first
tested in relatively low glucose (2.8 mM) in duplicate, with high
reproducibility (r2 = 0.80), and clear separation of the positive
and negative controls (Figure 3A).
When ranked by mean Z score, approximately 300 com-
pounds increased secretion of luciferase compared to DMSO
controls (Table S1, top). Of these, 48 had a greater Z score
than IBMX, and one had a greater Z score than potassium chlo-
ride. Several classes of compounds were enriched among the
top-scoring 100 small molecules, including the following: anti-
cholinergics/first-generation antihistamines, sodium channel
blockers, and prostaglandin antagonists (Figure 3B, in red at
top). In addition, all ten of the sulfonylureas present in the library
scored within the top 55 compounds, with most falling within the
top 25 (Table 1). Numerous small molecules used clinically for
conditions other than diabetes and without known links to
beta-cell function also scored highly.
At the other end of the spectrum, 130 compounds decreased
secretionof luciferasecompared toDMSOcontrols (TableS1,bot-
tom). Classes of small molecules enriched in the bottom-scoringc.
Table 1. Top-Scoring 25 Compounds from the Low and High Glucose Screens
Screen in Low (2.8 mM) Glucose Screen in High (8.3 mM) Glucose
Compound Class Compound Class
1 tyrothricin antibiotic 1 colforsin adenylyl cyclase agonistb
2 nateglinide sulfonylureaa 2 milrinone PDE inhibitorb
3 cinromide antiepileptic 3 benoxinate local anesthetic
4 glyburide sulfonylureaa 4 levosimendan calcium sensitizer
5 dyphylline PDE inhibitorb 5 artemisinin antimalarial
6 glipizide sulfonylureaa 6 anagrelide PDE inhibitorb
7 chlorpropamide sulfonylureaa 7 doramectin GABAergic agonist
8 meglumine amino sugar 8 deracoxib COX-2 inhibitor
9 acetohexamide sulfonylureaa 9 clofarabine guanosine analog
10 orphenadrine anticholinergic; antihistamine 10 methacholine muscarinic agonist
11 simvastatin HMGCR inhibitor (statin) 11 nialamide nonselective MAOI
12 betamethasone glucocorticoid 12 irsogladine PDE inhibitorb
13 triprolidine anticholinergic; antihistamine 13 estropipate estrogen + GABAergic agonist
14 chlorpheniramine anticholinergic; antihistamine 14 famciclovir guanosine analog
15 aceclidine muscarinic agonist 15 triamterene diuretic
16 ipratropium anticholinergic; antihistamine 16 ornidazole antifungal
17 repaglinide sulfonylureaa 17 acetarsol arsenoid
18 levosimendan calcium sensitizer 18 zaleplon GABAergic agonist
19 nadide NAD+ 19 cilostazol PDE inhibitorb
20 piroctone olamine antifungal 20 flopropione serotonin receptor antagonist
21 phenazopyridine local anesthetic 21 rofecoxib COX-2 inhibitor
22 tolbutamide sulfonylureaa 22 phenolphthalein calcium entry (SOCE) inhibitor
23 phentolamine alpha-adrenergic antagonist 23 proxyphylline PDE inhibitorb
24 methacholine muscarinic agonist 24 mefexamide psychostimulant
25 quinine K channel antagonista 25 griseofulvin antifungal
Left: compounds found to increase luciferase secretion in the presence of low (2.8 mM) glucose, as ranked by Z score. Right: compounds found
to increase luciferase secretion in the presence of high (8.3 mM) glucose, as ranked by Z score. PDE, phosphodiesterase inhibitor; HMGCR, 3-hy-
droxy-3-methyl-glutaryl-CoA reductase; NAD+, nicotinamide adenine dinucleotide; K, potassium; GABA, gamma-aminobutyric acid; COX-2,
cyclooxygenase-2; MAOI, monoamine oxidase inhibitor; SOCE, store-operated calcium entry.
aDenotes compounds that close potassium channels.
bDenotes compounds that increase cAMP.100 compounds included some expected agents: antifungals/
antibacterial agents, antidopaminergics/anticholinergics, calcium
channel blockers, alpha-adrenergic receptor agonists, and anti-
parasitic mitochondrial toxins (Figure 3B, in blue at bottom). Pro-
gestin analogs and selective estrogen receptor modulators
(SERMs) also inhibited luciferase secretion at this relatively low
glucose, as did PPAR-alpha agonists (fibrates) and several dopa-
minergic agonists.
Repeating Pilot Chemical Screen in High Glucose
To determine if our luminescent assay could be useful for identi-
fying insulin secretagogues that augment insulin release in the
setting of hyperglycemia, as required for a treatment for dia-
betes, we repeated the compound screen in INS-1E cells using
a supraphysiologic glucose concentration (8.3 mM), three times
higher than the initial screen. As expected, the baseline secretion
of luciferase in this assay was increased at this higher glucose
level. Similar to the low-glucose setting, high reproducibility
was observed between replicates (r2 = 0.90), with clear separa-
tion of positive and negative controls (Figure 4A).CellIn contrast to the original screen in low glucose, the screen
in high glucose identified few compounds that increased secre-
tion of luciferase above baseline. When ranked by mean Z
score, only 30 compounds increased luciferase secretion
compared to DMSO controls, and none scored higher than
the positive control, IBMX (Table S2, top). The classes of com-
pounds enriched among these top-scoring small molecules
were largely distinct from those identified in the low-glucose
screen, including the following: cAMP-inducing agents,
GABAergic agonists, ion channel modulators, prostaglandin an-
tagonists, and serotonergic antagonists (Figure 4B, in red at
top). Two guanosine analogs also scored highly in the screen,
as did one cholinergic agonist (Table 1). Sulfonylureas were
notably absent from the top-ranked compounds in this high-
glucose screen.
In the high-glucose assay, considerably more compounds
decreased secretion of luciferase, with 514 small molecules
scoring less than the lowest DMSO control (Table S2, bottom).
The classes of compounds enriched at this end of the spectrum
were largely similar to the low-glucose screen, with the 100Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inc. 131
Figure 4. High-Throughput Chemical Screen Performed in High Glucose Identifies Small Molecules that Amplify or Inhibit Insulin Secretion
(A) Results of a high-throughput screen of 1,600 known bioactive compounds for effects on luciferase secretion from INS-1E cells expressing the proinsulin-
luciferase construct, in the presence of high glucose (8.3 mM), with linear correlation between replicates (r2 = 0.90); test compounds (blue), DMSO negative
controls (green), IBMX (100 mM) positive control (red). Boxed area shown in greater detail below.
(B) Analysis by class of the 30 top-scoring (red) and 100 bottom-scoring (blue) compounds in the screen, based on reportedmechanisms. Number of compounds
in each class is shown. Abbreviations as in Figure 3, plus: GABA, gamma-aminobutyric acid; ACE, angiotensin-converting enzyme; a1-AR, alpha-1-adrenergic
receptor; a2-AR, alpha-2-adrenergic receptor. See also Figure S4 for comparison of high-throughput screening results in INS-1E and MIN6 cells.bottom-scoring compounds including the following: anticholin-
ergics/antidopaminergics, antifungals/antibacterial agents, cal-
cium channel blockers, ion channel modulators, antiparasitic
mitochondrial toxins, and alpha-2 adrenergic receptor agonists
(Figure 4B, in blue at bottom). In addition, several commonly pre-
scribed medications appeared to inhibit glucose-stimulated
luciferase secretion, including several angiotensin-converting
enzyme (ACE) inhibitors, the PPAR-a agonist fenofibrate, the
PPAR-g agonist pioglitazone, SERMs, progestogens, thyroid
hormones, and SSRIs.
To determine if the findings from the high-throughput assays
performed in rat INS-1E cells were specific to this cell line or spe-
cies, we repeated both the low- and high-glucose screens using
mouse MIN6 cells expressing the luminescent reporter. A high
degree of overlap was observed between the compounds and
related drug classes impacting luciferase secretion (Figure S4).
Validating Compounds on Human Islets
To determine if the secretagogues observed in the rodent cell
lines were relevant to human biology, we next tested top-scoring
small molecules fromour high-glucose screen for effects on insu-132 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inlin secretion in human pancreatic islets. To enable a reproducible
assessment of compound activity across multiple islets, human
islets were gently dissociated and seeded in 96-well format on
extracellular matrix (ECM)-coated plates (Walpita et al., 2012),
achieving a uniformdistribution of beta cells across the plate (Fig-
ure S5). The cells remained firmly attached throughout the subse-
quent wash steps, stimulations, and supernatant harvesting,
enabling us to evaluate compounds in parallel with minimal
well-to-well variability in beta cell number.
Applying thisapproach, sevencompounds identified in thehigh-
glucose screen as increasing luciferase secretion were tested
in dissociated human islets: milrinone, forskolin (equivalent to col-
forsin), anagrelide, ornidazole, cilostazol, pranoprofen, and be-
noxinate. Compounds were selected that demonstrated a range
of responses in our primary screen, including top hits as well as
relatively lower-scoring compounds, to enable an assessment of
the sensitivity of the assay in identifying human insulinotropics of
various potencies. To evaluate relative glucose dependence,
each compound was tested at three glucose levels, 1.67 mM
(low), 5.6mM(normal), and16.7mM(high), usingdissociated islets
from each of four nondiabetic cadaveric donors (Table S5).c.
Figure 5. Effects of Compounds from High-Glucose Screen on Insulin Secretion from Human Islets
Seven insulinotropic compounds identified as increasing luciferase secretion from INS-1E cells in the high-glucose screen were tested for effects on insulin
secretion from dissociated human islets in the context of three glucose concentrations (1.67 mM, 5.6 mM, 16.7 mM); data represent mean ± SD (n = 4).
Compounds are ranked by their effect in 16.7 mM glucose, averaged across donors. (A)–(D) represent four independent, nondiabetic islet donors.
See also Figure S5, demonstrating the homogeneous distribution of dissociated human islets used for compound testing; Figure S6, showing the correlation
between compound rank in the INS-1E screen and in human islet experiments; and Table S5, summarizing the human islet donor information.All seven compounds were found to consistently increase
secretion of insulin from human beta cells (Figure 5) in largely
the same order of effect as seen in the primary screen in INS-1E
cells (Figure S6). While the effect of each compound was potenti-
ated by glucose, none of the compounds were strictly glucose
dependent at the relatively high concentrations used in the assay.
Milrinone, a phosphodiesterase inhibitor (PDEI) with known links
to beta-cell function (Parker et al., 1997), increased insulin secre-
tion more than the other compounds. Forskolin, an activator of
adenylyl cyclase, increased secretion in all glucose levels tested.
Anagrelide, a PDEI used clinically for essential thrombocytosis,
was nearly as effective as forskolin in inducing secretion of insulin
at high glucose, but produced less of an effect at low glucose. The
remaining compounds, including an antiprotozoal agent (ornida-
zole), another PDEI (cilostazol), anNSAID (pranoprofen), and a so-
dium channel antagonist (benoxinate), also augmented insulin
secretion in a glucose-potentiated manner.
Investigating the Inhibitory Effect of Fenofibrate on
Insulin Secretion
One of the compounds identified in our high-glucose screen that
strongly inhibited luciferase secretion, the PPAR-a agonist feno-
fibrate, is of particular interest because of its widespread clinical
use in patients with the metabolic syndrome. To further evaluateCellthe effect of this compound on beta-cell function, we tested it in
dose on the INS-1E reporter cell line, across varying glucose
concentrations (Figure 6A). The compound dramatically inhibited
secretion, in a dose-dependent manner, with more pronounced
effects at concentrations approaching its EC50 (18 mM in rodent
cells). To determine if this effect was relevant to human beta
cells, we next tested the compound on dissociated human islets,
across varying glucose concentrations, and at concentrations up
to its EC50 (50 mM in human cells). We observed robust inhibition
of GSIS, again in a dose-dependent manner, across multiple in-
dependent pancreatic islet donors (Figures 6B and 6C).
Next, to determine if the compound was blocking secretion by
acting proximal or distal to the depolarization of the beta cell, we
tested its effect on KCl-mediated luciferase secretion from the
INS-1E reporter cells. Similar to somatostatin, an established in-
hibitor of insulin secretion with multiple effects in the beta cell
(Hsu et al., 1991), fenofibrate severely inhibited secretion of lucif-
erase under maximal KCl-mediated stimulation (Figure 6D),
implying the presence of an effect late in the exocytotic pathway.
Cells treated with fenofibrate during these assays had no
obvious morphologic changes, but to more thoroughly evaluate
if the compoundwas toxic to beta cells, wemeasured the cellular
ATP content of fenofibrate-treated INS-1E cells using the Cell-
Titer-Glo reagent (Figure 6E). No significant change in ATPMetabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inc. 133
Figure 6. Fenofibrate Decreases Glucose-Stimulated Luciferase Secretion, Insulin Secretion, and cAMP Levels in a Dose-Dependent
Manner without Affecting Cellular ATP Levels
(A) Fenofibrate inhibits glucose-stimulated luciferase secretion from INS-1E cells in a dose-dependent manner. The effect of the compound was tested in the
context of four glucose concentrations (2.8 mM, 5.6 mM, 11.1 mM, 16.7 mM); data represent mean ± SD (n = 4).
(B and C) Fenofibrate inhibits glucose-stimulated insulin secretion from dissociated human pancreatic islets in a dose-dependentmanner; data represent mean ±
SD (n = 4). Each plot shows data from an independent, nondiabetic islet donor.
(D) Fenofibrate decreases KCl-stimulated luciferase secretion from INS-1E cells, comparable to somatostatin, a known inhibitor of KCl-stimulated insulin
secretion. Data represent mean ± SD (n = 8; two-tailed paired Student’s t test in relation to DMSO; * < 105, ** < 108).
(E) Fenofibrate has no effect on cellular ATP in INS-1E cells, as measured using the CellTiter-Glo assay after 1 hr incubation with varying concentrations of the
compound. Data represent mean ± SD (n = 8).
(F) Fenofibrate decreases cAMP levels in a dose-dependent manner, in INS-1E cells stimulated with forskolin (1 mM) and IBMX (500 mM), similar to somatostatin.
Data represent mean ± SD (n = 4; two-tailed paired Student’s t test in relation to DMSO; * < 0.002). See also Table S5, summarizing the human islet donor in-
formation.content was observed at concentrations up to 50 mM. In
contrast, whenwemeasured cAMP levels in cells treated with fe-
nofibrate, we saw a dramatic decrease in this key secondary
messenger, greater than the effect of somatostatin (Figure 6F).
This effect is likely independent of the compound’s agonism of
PPAR-a, as other compounds in the same class, including gem-
fibrozil and 9-oxo-10(E),12(E)-octodecadienoic acid, had no ef-
fect on insulin secretion (data not shown).
DISCUSSION
Here we describe the creation, validation, and application of a
luminescent insulin secretion reporter that facilitates large-scale134 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inassays of beta-cell function. The assay takes advantage of the
endogenous proinsulin-processing pathway to target Gaussia
luciferase to the secretory vesicles within the beta cell. In
contrast to the insulin ELISA, the luminescent reporter is fast,
inexpensive, and amenable to high-throughput applications in
a homogeneous format. In addition to detecting insulin secreta-
gogues, the reporter provides a rapid and straightforward
readout of beta-cell dysfunction. As such, it may enable the dis-
covery of compounds or genetic factors protecting against these
insults, helping to shed light on the molecular mechanisms by
which insulin secretion declines in diabetes.
We demonstrated the utility of the assay by performing pilot
screens of 1,600 bioactive compounds and natural products,c.
in both low and high glucose, and in both rat INS-1E and mouse
MIN6 beta-cell lines. While these screens were limited to known
bioactives, and thus not designed to discover novel small mole-
cules with activity on beta cells, they may nonetheless help to
identify pathways of relevance to human beta-cell function.
Indeed, in each glucose level tested, several classes of com-
pounds emerged as augmenting or inhibiting luciferase release,
many without prior links to insulin secretion. Numerous com-
pounds increased insulin secretion in the low-glucose screen,
whereas very few increased secretion in themore physiologically
relevant high-glucose screen, likely a reflection of the distinct
mechanisms by which secretion is enhanced in each setting. In
low glucose, beta cells are in a polarized resting state, and com-
pounds that shift the membrane potential toward depolarization
increase secretion, as suggested by the strong effects of sulfo-
nylureas and sodium channel modulators. In high glucose, how-
ever, the beta cells are already depolarized, so compounds
that trigger depolarization have minimal additional impact on
secretion. In this setting, compounds that augment the amp-
lifying pathway of insulin secretion have more prominent ef-
fects, such as cAMP-inducing agents (Almahariq et al., 2014),
GABAergic agonists (Bansal et al., 2011), and 5-HT1A serotonin
receptor antagonists (Uvna¨s-Moberg et al., 1996).
Several intriguing classes of compounds emerged as in-
creasing luciferase secretion, including the following: (in low
glucose) anticholinergics/first-generation antihistamines, NSAIDs,
and statins; (in high glucose) COX-2 inhibitors, angiotensin recep-
tor blockers (ARBs), and guanosine analogs. Supporting the plau-
sibility of these findings, theM2 andM4muscarinic receptors (Mi-
guel et al., 2002), as well as certain prostaglandin receptors (Fujita
et al., 2007; Kimple et al., 2013), have been reported to negatively
regulate insulin secretion. Likewise, statins may increase insulin
secretion in low-glucose conditions (Ishikawa et al., 2006),
andARBs improveGSIS in human subjects, reducing the progres-
sion to diabetes in subjects with impaired glucose metabolism
(van der Zijl et al., 2011). Guanosine analogs may increase the
amount of guanosine triphosphate in beta cells, which can directly
stimulate insulin secretion (Wollheim and Maechler, 2002).
Our screens also identified classes of compounds that
decreased luciferase secretion, including some common medi-
cations that have been implicated previously in inhibiting insulin
release: SERMs (Le May et al., 2006), progestogens (Shao et al.,
2004), SSRIs (Isaac et al., 2013), and the PPAR-gamma agonist
pioglitazone (Lamontagne et al., 2009). The PPAR-a agonist fe-
nofibrate, not previously known to affect beta-cell function,
was found to robustly block glucose-mediated stimulation of
secretion in both rodent and human beta cell models in a
dose-dependent manner. Prior reports of fenofibrate’s effects
on beta cells are conflicting, with one group describing a stimu-
latory effect on hamster insulinoma cells (Shimomura et al., 2004)
and another group demonstrating an inhibitory effect in long-
term cultures of mouse islets (Liu et al., 2011). Our results
show that the drug acutely decreases insulin secretion at clini-
cally relevant concentrations, possibly through an inhibitory ef-
fect on cAMP, and likely independent of its agonism of PPAR-a.
While a number of compounds identified as agonists and an-
tagonists of luciferase secretion in our screen are in clinical
use, few have been reported to affect insulin or glucose levels.
Possible explanations for this discrepancy include the following:Cell(1) the relatively high concentrations of compounds used in this
screen relative to their expected serum levels in patients; (2)
the effect of in vivo drug metabolism on compound activity;
(3) a limitation of using rodent beta-cell lines and/or isolated
cadaveric islets to model complex human biology; (4) as-yet un-
appreciated side effects of these medications. The luminescent
reporter may help to identify effects of medications on beta-cell
function that have not been recognized clinically, by creating hy-
potheses that can be further evaluated using the appropriate
clinical and translational research tools (e.g., electronic medical
record databases, animal models).
While advantageous for the applications described, the lumi-
nescent insulin secretion assay has several limitations. First, it
does not detect changes in expression of insulin, but rather, like
the ELISA, monitors hormone secretion. Perturbations affecting
insulin promoter activity alone, such as those caused by certain
beta cell toxins, may not be identified using the reporter. Second,
the assay relies on the expression of our fusion construct in an
appropriate beta-cell model. We have used well-validated rodent
beta-cell lines as surrogates for the human beta cell, yet impor-
tant differences in beta-cell function exist between species, as
well as between transformed cell lines and primary cells. All re-
sults must therefore be confirmed using primary human islets
and an insulin immunoassay, as we have done. Notably, the re-
porter appears to function well in human beta cells, and
continued efforts to generate functional human beta-cell lines
offer the potential to deploy our reporter in an even more relevant
biological context. Third, the expression of the luminescent re-
porter itself may impact aspects of beta-cell function in subtle
ways that could influence experimental results. Though we
confirmed that C-peptide secretion from reporter-containing
INS-1E cells is similar to that from wild-type cells, we cannot
rule out an effect of the constitutive expression of the fusion pro-
tein on other functional readouts, such as the ER stress response.
In summary, we have shown that a fusion protein in which
Gaussia luciferase is placed within the C-peptide portion of the
insulin prohormone can be used to create a high-throughput
luminescent assay of beta-cell function, enabling large-scale ex-
periments that have historically been impractical. Application of
this assay to larger, unbiased compound screens may help to
characterize the molecular mechanisms governing insulin
release, as well as to identify therapeutic leads for preserving
and improving beta-cell function in diabetes. Additional re-
porters based on prohormone-luciferase fusion proteins may
also prove useful to monitor the secretion of other peptide hor-
mones relevant to metabolic disease for which immunoassays
are currently limiting.EXPERIMENTAL PROCEDURES
Cell Culture
MIN6 cells were a gift from Dr. Jun-ichi Miyazaki (Osaka University) and were
maintained in DMEM with 4.5 g/l glucose, supplemented with 10% heat-inac-
tivated fetal bovine serum and 55 mM beta-mercaptoethanol (Sigma). INS-1E
cells were a gift from Dr. Claes Wollheim and Dr. Pierre Maechler (University
of Geneva) and were maintained in RPMI with 2 g/l glucose, supplemented
with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 2 mM
L-glutamine, 10 mM HEPES, and 55 mM b-mercaptoethanol (Invitrogen). Cells
were grown on tissue culture-treated plastic and dissociated with TrypLE
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Proinsulin-Luciferase Construct
The proinsulin-luciferase fusion construct was created by Gibson Assembly in
the pUC19 vector using two gBlocks (Integrated DNA Technologies) encoding
the protein andGibson AssemblyMaster Mix (NewEngland Biolabs). The proin-
sulin-luciferase fusion construct was subsequently PCR-amplified with primers
to add attB1 and attB2 sites, inserted by BP Clonase II into the Gateway Entry
vector pDONR223 (Invitrogen), and then shuttled by LR Clonase II into the
GatewayDestinationvectorpLX304 (Yanget al., 2011;Addgeneplasmid25890).
Lentiviral Infection
Lentivirus expressing each prohormone-luciferase fusion protein was pro-
duced using a second-generation viral packaging system and used to infect
rodent beta-cell lines or human islets, as described in the Supplemental Exper-
imental Procedures.
Immunofluorescence
Cultures were fixed, permeabilized, and stained with antibodies to Gaussia
luciferase (NanoLight) and insulin (Sigma), as described in the Supplemental
Experimental Procedures. Cultures were then incubated in secondary anti-
bodies (Alexa Fluor-conjugated anti-rabbit and anti-guinea pig; Invitrogen),
and images were acquired by confocal microscope.
Secretion Assays
For standard secretion assays, MIN6 and INS-1E cells were plated in 96-well
format, preincubated for 1 hr in Krebs Ringer Buffer (KRB) with 2.8 mM
glucose, and then stimulated for 1 hr in fresh KRB containing varying amounts
of glucose and compounds, as described in the Supplemental Experimental
Procedures. Insulin or C-peptide concentration was determined using an
ELISA (Mercodia), following the manufacturer’s protocol. Luciferase activity
was determined from the same samples by adding the coelenterazine sub-
strate (NanoLight) to the supernatant to a final concentration of 10 mM and
reading on a standard plate reader (BioTek).
Inducing Beta-Cell Dysfunction
INS-1E cells were treated with cytokines, palmitate, or the ER stress-inducing
agent thapsigargin to induce cellular dysfunction. For cytokine treatment, we
used a mixture that included 10 ng/ml of IL-1b, 50 ng/ml of IFN-g, and
25 ng/ml of TNF-a (R&D Systems), referred to as the ‘‘1X’’ concentration, dis-
solved in standard INS-1E growth medium. For palmitate treatment, we dis-
solved the fatty acid (Sigma) to 50 mM in 90% ethanol at 60C for several
hours, and then diluted this stock in RPMI containing 1%BSA, with all samples
receiving the same amount of BSA. For thapsigargin treatment, we dissolved
the compound (Sigma) to 1mM in DMSO and then diluted this stock solution in
RPMI containing 1% BSA. Cells were incubated for 24 hr in cytokines and
palmitate, or 8 hr in thapsigargin, prior to performing the GSIS assay.
Small Molecule Screens
MIN6 and INS-1E cells were expanded to 80% confluence in their respective
growth media, washed once in PBS, and preincubated for 1 hr at 37C in KRB
with 2.8 mM glucose. Cells were then dissociated, spun at 300 3 g for 2 min,
resuspended in fresh KRB without glucose, and filtered through 40 mm mesh
(Becton Dickinson). Next, the cells were counted and diluted in KRB to
13106 cells per ml, and glucose was added as required for each experiment.
Cells were then seeded in 384-well format, 33104 cells in 30 ml per well, using a
Multidrop Combi device (Thermo Scientific). Compounds from the Pharmakon
1,600 Collection (MicroSource Discovery Systems) were pinned into each well
using a Vario robot (CyBio) to a final concentration of 30 mM, and the plates
were then incubated for 2 hr at 37C. For assays involving a transfer step,
the plates were then centrifuged at 3003 g for 2 min, and 20 ml of supernatant
was transferred to a new 384-well plate. Coelenterazine substrate was then
added to a final concentration of 10 mM, and luciferase activity was determined
using a standard plate reader (BioTek).
Fenofibrate Investigation
Fenofibrate, gemfibrozil, and 9-oxo-10(E),12(E)-octodecadienoic acid
(Cayman Chemical) were resuspended in DMSO, as were forskolin and
IBMX (Sigma). Somatostatin-14 (Sigma) was resuspended in sterile water.
CellTiter-Glo (Promega) and the cAMP Dynamic-2 HTRF assay (Cisbio) were136 Cell Metabolism 21, 126–137, January 6, 2015 ª2015 Elsevier Inused according to the manufacturers’ instructions. Luciferase secretion and
CellTiter-Glo experiments were performed using a 1 hr incubation with com-
pound, whereas the cAMP assay was performed using a 30 min incubation.
Secretion experiments were run in KRB buffer; all other experiments were
run in standard INS-1E medium.
Statistical Analysis
For the high-throughput screens, a row-based correction factor was applied to
all luciferase readings to adjust for logarithmic signal decay, and then a score
similar to the statistical Z score for each test compound was calculated, as
described in the Supplemental Experimental Procedures.
Human Islet Cell Culture
Human islets were obtained through the Integrated Islet Distribution Program
(http://iidp.coh.org) and from Prodo Labs (Table S5). Islets were maintained
and dissociated in 96-well format as described (Walpita et al., 2012). To test
compounds for their effects on insulin secretion, the dissociated islets were
washed gently in KRB and preincubated for 1 hr at 37C in KRB with
2.8 mM glucose. The cells were then washed twice with zero-glucose KRB
and placed in 100 ml of fresh KRB with varied glucose concentrations plus
compounds. After a 1 hr incubation at 37C, the supernatant was removed,
and insulin concentration was measured by ELISA (Mercodia) according to
the manufacturer’s instructions.
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Experimental Procedures and can be found with this article online at http://
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